Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX

Thursday, 19 Oct 2017

Oct 19 (Reuters) - uniQure Nv :uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua).

Orexigen Therapeutics - pursuing potential actions including merger or sale of co

Monday, 16 Oct 2017

Oct 16 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​.Orexigen Therapeutics-‍management evaluating whether there are relevant conditions to raise substantial doubt about co's ability to continue as going concern​.Orexigen Therapeutics-in connection with evaluation, ‍co currently pursuing number of potential actions, including attempting to pursue merger or sale of co.

Weifa shares gets approval of guarantee for compulsory acquisition

Thursday, 12 Oct 2017

Oct 12 (Reuters) - WEIFA ASA ::COMPULSORY ACQUISITION - APPROVAL OF GUARANTEE.‍PRICE OFFERED UNDER COMPULSORY ACQUISITION IS NOK 35 PER SHARE​.

Co-Diagnostics to sign purchase agreement with Medcis Pathlabs

Tuesday, 5 Sep 2017

Sept 5 (Reuters) - Co-diagnostics Inc ::Co-Diagnostics, Inc to sign purchase agreement with Medcis Pathlabs.Co-Diagnostics- co, Medcis Pathlabs India Pvt. Ltd, have agreed to terms of purchase agreement for co-diagnostics products to be used throughout India.

Germany's Evotec to acquire U.S.-based Aptuit for 256 mln euros

Sunday, 30 Jul 2017

July 30 (Reuters) - Evotec AG :Evotec to acquire Aptuit, expanding leadership in external innovation.Consideration of about 256 million euros to be paid in cash from Evotec's balance sheet and through debt financing at highly attractive terms.

Can-Fite Biopharma, co's unit Ophthalix Inc and Wize Pharma enters into an agreement and plan of merger

Monday, 22 May 2017

May 22 (Reuters) - Can Fite Biopharma Ltd : :Can-Fite Biopharma Ltd - co's unit Ophthalix Inc, a unit of Ophthalix Bufiduck Ltd and Wize Pharma Ltd entered into an agreement and plan of merger.Can-Fite Biopharma Ltd -each outstanding ordinary share of Wize will be converted into the right to receive 5.3681 of Ophthalix's common stock.Can-Fite Biopharma Ltd - Ophthalix Bufiduck Ltd will merge with and into Wize, with Wize becoming a wholly-owned subsidiary of Ophthalix.Can-Fite Biopharma - Wize shareholders are expected to own about 90pct of Ophthalix while Ophthalix stockholders are expected to own remaining about 10pct.

Essex Bio-Technology enters research project deal with AC Immune

Monday, 22 May 2017

May 22 (Reuters) - Essex Bio-technology Ltd <1061.HK>:Company entered into research project agreement with ACI.Deal to collaborate in pre-clinical and clinical co-development of novel biological therapeutic to treat neurodegenerative diseases.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary